Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0KNBNI
ADC Name	CN109310781A ADC-6
Synonyms	CN109310781A_ADC-6 Click to Show/Hide
Organization	Bayer Pharma AG
Drug Status	Investigative
Indication	In total 1 Indication(s) Acute myeloid leukemia [ICD11:2A60] Investigative
Drug-to-Antibody Ratio	4.3
	3D MOL	2D MOL
Antibody Name	TPP-8988		Antibody Info
Antigen Name	Interleukin-3 receptor subunit alpha (IL3RA)		Antigen Info
Payload Name	Undisclosed
Linker Name	CN109310781A ADC-6 linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 63	%	CVCL_2119	Adult acute myeloid leukemia
Tumor Growth Inhibition value (TGI)	≈ 75	%	CVCL_0064	Childhood acute monocytic leukemia

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	16.7	pM	CVCL_2119	Adult acute myeloid leukemia
Half Maximal Inhibitory Concentration (IC50)	0	nM	CVCL_0064	Childhood acute monocytic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.00% (Day 14)	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MOLM 13 CDX model
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.00% (Day 21)	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MV4-11 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16.70 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay. Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.19 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay. Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

References

Ref 1	Specific antibody-drug-conjugate (ADC) with KSP inhibitor and anti-CD123- antibody.